Completed PHASE3 INTERVENTIONAL 2-arm NCT04224207

Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells (WJ-MSC)

Management of Retinitis Pigmentosa by Wharton's Jelly Derived Mesenchymal Stem Cells: Preliminary Clinical Results

Sponsor: Ankara Universitesi Teknokent

Conditions Inherited Retinal Dystrophy Retinitis Pigmentosa

Interventions Wharton's jelly derived mesenchymal stem cell

Updated 5 times since 2020 Last updated: Jan 8, 2020 Started: Apr 1, 2019 Primary completion: Oct 30, 2019 Completion: Jan 1, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Inherited Retinal Dystrophy and Retinitis Pigmentosa and is currently completed. Ankara Universitesi Teknokent leads this study, which shows 5 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Feb 2020 — Jan 2021 [monthly]

Completed PHASE3

First recorded

Apr 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ankara Universitesi Teknokent

Data source: Ankara Universitesi Teknokent

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ankara, Turkey (Türkiye)